Recent Posts
- Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
- Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference
- AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
- Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept